US Department of Defense (DoD) to support TRAUMAKINE development
· The DoD grants $6.1 million for the HIBISCUS study · Faron and the US Air Force to explore Traumakine’s wider potential to prevent multi-organ failure after ischemia and reperfusionCompany announcement, 18 January 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the US Department of Defense (“DoD”) has selected the HIBISCUS Study to receive $6.1 million of funding from the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The Phase II/